RGNX
Closed
Regenxbio Inc
8.23
+0.02 (+0.24%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 8.21
Day's Range: 7.91 - 8.5
Send
sign up or login to leave a comment!
When Written:
17.26
Regenxbio Inc. is a clinical-stage biotechnology company focused on the development of gene therapy treatments for a wide range of genetic disorders. The company was founded in 2008 and is headquartered in Rockville, Maryland.
Regenxbio's gene therapy platform is based on the use of adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target cells. The company has developed a proprietary AAV vector technology called NAV Technology Platform, which allows for the production of high-quality, consistent, and scalable AAV vectors.
Regenxbio's lead product candidate is RGX-314, a gene therapy for the treatment of wet age-related macular degeneration (wet AMD). The company is also developing gene therapies for the treatment of other ophthalmic diseases, as well as genetic disorders such as Fabry disease, Hunter syndrome, and mucopolysaccharidosis type II.
Regenxbio has partnerships with several pharmaceutical companies, including Biogen, Novartis, and Pfizer, for the development and commercialization of its gene therapy products. The company went public in 2016 and is listed on the NASDAQ stock exchange under the ticker symbol RGNX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Regenxbio's gene therapy platform is based on the use of adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target cells. The company has developed a proprietary AAV vector technology called NAV Technology Platform, which allows for the production of high-quality, consistent, and scalable AAV vectors.
Regenxbio's lead product candidate is RGX-314, a gene therapy for the treatment of wet age-related macular degeneration (wet AMD). The company is also developing gene therapies for the treatment of other ophthalmic diseases, as well as genetic disorders such as Fabry disease, Hunter syndrome, and mucopolysaccharidosis type II.
Regenxbio has partnerships with several pharmaceutical companies, including Biogen, Novartis, and Pfizer, for the development and commercialization of its gene therapy products. The company went public in 2016 and is listed on the NASDAQ stock exchange under the ticker symbol RGNX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!